Compare KKR & Co Inc (KKR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? KKR & Co Inc trades at $85.5 (market cap $78.24B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: KKR & Co Inc is far larger — about 10.4× Spyre Therapeutics Inc. Common Stock's market cap, and KKR & Co Inc pays a 0.89% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KKR | SYRE | |
|---|---|---|
Market Cap | $78.24B | $7.52B |
Volume | 9,217,096 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $142.75 | $108.92 |
52-Week Low | $83.88 | $22.18 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $795.68M | $6.52B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR's stock is trading at $85.60, down 6.46% in the last session amid a bearish technical outlook. The company maintains strong profitability with a 14.97% net income margin and has beaten earnings estimates in two of the last three quarters. Recent business developments include multiple strategic investments and joint ventures, including a partnership with Thomson Reuters and new equipment finance platform Akrapoint Commercial Capital.
Despite near-term price weakness, KKR presents a compelling investment case with strong analyst support (88.9% buy ratings) and a consensus price target of $123.20 representing 44% upside. Key risks include volatile cash flow patterns and high leverage, but the company's diversified investment platform and active deal pipeline support long-term growth prospects.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
